Obsidian Therapeutics to Begin Trading on Nasdaq After Reverse Merger with Galera Therapeutics
Obsidian Therapeutics, a biotechnology company, will start trading on the Nasdaq following a reverse merger with Galera Therapeutics. The combined entity will focus on developing Obsidian’s cell therapy OBX-115, which is in clinical trials for advanced melanoma and non-small cell lung cancer. The merger is supported by a $350 million private placement financing.
Tickers: $IOVA
Topics: biotechnology cell therapy clinical trials funding reverse merger